Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Most companies are taking a cautious “wait-and-see” attitude, although several are now aggressively pursuing policy sales from other terminally ill populations.
Treatments fashioned specifically for rare diseases are necessarily very expensive. A fully satisfactory solution to this problem has not yet been found.
